Attaining biochemical euthyroidism early after total thyroidectomy in Graves’ disease may lower long-term morbidity risk

Xiaodong Liu1, Carlos K. H. Wong2,3,4, Wendy W. L. Chan5, Eric H. M. Tang3, Yu Cho Woo6, Shirley Y. W. Liu7, Cindy L. K. Lam3 and Brian H. H. Lang1*

1Department of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People’s Republic of China
2Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People’s Republic of China
3Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People’s Republic of China
4Laboratory of Data Discovery for Health, Hong Kong Science Park, New Territories, Hong Kong SAR, People’s Republic of China
5Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People’s Republic of China
6Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People’s Republic of China
7Division of Endocrine Surgery, Department of Surgery, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, People’s Republic of China

*Correspondence to: Brian H. H. Lang, Division of Endocrine Surgery, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, People’s Republic of China (e-mail: blang@hku.hk)

Abstract

Background: The relationship between good early control of thyroid hormone levels after thyroidectomy for Graves’ disease (GD) and subsequent risks of mortality and morbidities is not well known. The aim of this study was to examine the association between thyroid hormone levels within a short interval after surgery and long-term mortality and morbidity risks from a population-based database.

Methods: Patients with GD who underwent complete/total thyroidectomy between 2006 and 2018 were selected from the Hong Kong Hospital Authority clinical management system. All patients were classified into three groups (euthyroidism, hypothyroidism, and hyperthyroidism) according to their thyroid hormone levels at 6, 12, and 24 months after surgery. Cox proportional hazards models were performed to compare the risks of all-cause mortality, cardiovascular disease (CVD), Graves’ ophthalmopathy, and cancer.

Results: Over a median follow-up of 68 months with 5709 person-years, 949 patients were included for analysis (euthyroidism, n = 540; hypothyroidism, n = 282; and hyperthyroidism, n = 127). The hypothyroidism group had an increased risk of CVD (HR = 4.20, 95 per cent c.i. 2.14, 95 per cent c.i. 1.55 to 2.97, P < 0.001) and the hyperthyroidism group had an increased risk of cancer (HR = 2.14, 95 per cent c.i. 1.55 to 2.97, P < 0.001) compared with the euthyroidism group. Compared with patients obtaining euthyroidism both at 6 months and 12 months, the risk of cancer increased in patients who achieved euthyroidism at 6 months but had an abnormal thyroid status at 12 months (HR = 2.33, 95 per cent c.i. 1.51 to 3.61, P < 0.001) and in those who had abnormal thyroid status at 6 months but achieved euthyroidism at 12 months (HR = 2.52, 95 per cent c.i. 1.60 to 3.73, P < 0.001).

Conclusions: This study showed a higher risk of CVD in postsurgical hypothyroidism and a higher risk of cancer in hyperthyroidism compared with achieving euthyroidism early after thyroidectomy. Patients who were euthyroid at 6 months and 12 months had better outcomes than those achieving euthyroidism only at 6 months or 12 months. Attaining biochemical euthyroidism early after thyroidectomy should become a priority.

Introduction

Graves’ disease (GD) is the most prevalent cause of thyrotoxicosis and the prevalence varies from 1 to 1.5 per cent of the general population. Anti-thyroid drugs (ATDs) are an effective initial treatment but persistent or relapsed GD occurs in half of the patients when ATDs are withdrawn. A more definitive treatment such as radioiodine therapy (I-131) or surgery (near-total or total thyroidectomy) is recommended for patients with persistent or relapsed GD. One key benefit of surgery over other treatments is the rapid control of hyperthyroidism and this may lead to better patient outcomes over time. However, attaining euthyroidism with levothyroxine replacement early after surgery is often difficult because of the long half-life of levothyroxine, narrow therapeutic window, variations in bioavailability and pharmacodynamics, and non-compliance to treatment. One previous study reported the average time of attaining biochemical euthyroidism after surgery to be more than 3 months. Therefore, early monitoring of thyroid hormones, including serum thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels is important after surgery.

Although it has been reported that patients with long-standing mild hypothyroidism or hyperthyroidism may have increased risks of cardiovascular disease (CVD) and cardiac death than individuals who are euthyroid, the relationship between...
good early control of thyroid hormone levels after thyroidectomy and subsequent risks of mortality and morbidity is not well known. With more recent studies favouring surgery as the preferred therapy for GD, further research evaluating the impact of postoperative thyroid status on the long-term outcomes in patients with GD is essential with the hypothesis that GD patients who could attain biochemical euthyroidism early after surgery may have lower all-cause mortality and morbidity risks over time than those who did not.

This study aimed to estimate the incidence of euthyroidism within a short interval after surgery and to determine the likely association between achieving biochemical euthyroidism early after complete or total thyroidectomy and the outcomes of all-cause mortality, CVD, Graves’ ophthalmopathy, and cancer in patients with GD.

Method

Study population

The authorized approval for this present study was obtained from the local institutional review board (UW 17–277). Data were collected from the territory-wide prospectively coded database (the Hong Kong Hospital Authority clinical management system (CMS)), which started in 1998. Connecting all 41 public hospitals and clinics, this electronic database system has a coverage rate of 90 per cent of all inpatient healthcare services in the region. The completeness rates of 100 per cent and 99.98 per cent of patients’ demographic and prescription details have been reported in previous research, validating the quality of the CMS dataset. A high positive predictive value also has been confirmed by checking the medical records. Given that certain data were not completely certified until 2005, the present study collected data from 1 January 2006 to 31 December 2018. During this interval, those having a diagnosis of GD who underwent total thyroidectomy and received oral levothyroxine replacement afterwards were included. ICD-9-CM diagnosis codes were used to determine the definition of GD, and ICD-9-CM procedure codes were used to identify thyroidectomy. Patients were excluded if they did not receive levothyroxine replacement therapy, had one time, or no test of postoperative thyroid hormones, had other thyroid status, had less than 12 months follow-up after surgery, or were aged under 18 years old.

Data regarding demographic characteristics were extracted including age, sex, BMI, thyroid hormone tests, systolic/diastolic blood pressure, serum triglyceride, serum low-density lipoprotein cholesterol, blood glucose, and estimated glomerular filtration rate. The disease duration of GD (from the diagnosis date of GD to the date of total thyroidectomy), previous treatment records of ATDs and radioactive iodine (RAI), drug dispensation of levothyroxine, comorbidity calculated by the Charlson comorbidity index (CCI), and outcome events of mortality and morbidity were also obtained. Outcome events and treatment procedures were identified using the ICD-9-CM and International Classification of Primary Care, version 2 (ICPC-2) codes (Table S1).

Group assignment

With 2–3 months after surgery, patients had their serum TSH and FT4 levels checked and these were repeated 6 months after surgery. Patients who did not receive LT4 treatment had only one or no test of TSH and FT4, had other thyroid status, had less than 12 months follow-up, or were aged under 18 years old. Patients with Graves’ disease who underwent thyroidectomy between 2006 and 2018

Patients with Grave’s disease who underwent thyroidectomy between 2006 and 2018 $n = 1428$

Patients who underwent thyroidectomy and received LT4 treatment $n = 1375$

Patients who had two or more tests of TSH and FT4 $n = 949$

Patients who had hypothyroidism at least twice at 6, 12, and 24 months after surgery $n = 282$

Patients who had euthyroidism at least twice at 6, 12, and 24 months after surgery $n = 540$

Patients who had hyperthyroidism at least twice at 6, 12, and 24 months after surgery $n = 127$

Patients who did not receive LT4 treatment $n = 53$

Patients who had only one or no test of TSH and FT4 $n = 262$, had other thyroid status $n = 138$, had less than 12 months follow-up $n = 24$ and aged under 18 years old $n = 2$

Fig. 1 Flow chart of Graves’ disease patients with different thyroid status after thyroidectomy

LT4, levothyroxine; FT4, free thyroxine; TSH, thyroid-stimulating hormone
surgery. Based on the definitions from previous studies, the identification of thyroid status in this present study was according to the serum TSH level (reference range 0.35–4.78 mIU/l) and FT4 level (reference range 12–23 pmol/l).

Patients with GD after thyroid surgery were categorized into the following groups according to their thyroid status:

- Euthyroidism group, which included patients with normal serum TSH and FT4 levels
- Hypothyroidism group, which included patients with overt hypothyroidism who had a TSH level of more than 4.78 mIU/l and an FT4 level below normal (<12 pmol/l) or those with subclinical hypothyroidism who had a TSH level of more than 4.78 mIU/l and a normal FT4 level (12–23 pmol/l)
- Hyperthyroidism group, which included patients with overt hyperthyroidism who had a TSH level of <0.35 mIU/l with an elevated FT4 level (>23 pmol/l) or those with subclinical hyperthyroidism who had a TSH level of <0.35 mIU/l and a normal FT4 level (12–23 pmol/l).

Given the fluctuation of thyroid hormone levels over time, the thyroid status at three pre-determined time points, including 6, 12, and 24 months was selected to determine the thyroid status in a short interval after surgery. If patients had the same diagnosis two or more times at these three pre-determined time points, they were categorized into the corresponding groups.

The study outcomes included all-cause mortality, CVD, Graves’ ophthalmopathy, and primary cancer. The index date of all

Table 1 Baseline characteristics of patients with Graves’ disease with different thyroid hormone levels after thyroidectomy

| Baseline characteristics | Total (n = 949) | Euthyroidism (n = 540) | Hypothyroidism (n = 282) | Hyperthyroidism (n = 127) | P |
|-------------------------|----------------|------------------------|--------------------------|--------------------------|---|
| General information     |                |                        |                          |                          |   |
| Age, (years) mean (s.d.)| 41.70 (12.67) | 43.04 (12.46)          | 37.89 (11.79)            | 44.50 (13.64)            | <0.001* |
| Age group               |                |                        |                          |                          | 0.006* |
| <60 years               | 809 (85.2)     | 451 (83.5)             | 256 (90.8)               | 102 (80.3)               |   |
| >60 years               | 140 (14.8)     | 89 (16.5)              | 26 (9.2)                 | 25 (19.7)                |   |
| Sex ratio (M:F)         | Female         | 727 (76.6)             | 425 (78.7)               | 195 (69.1)               | 107 (84.3) |
|                         | Male           | 222 (23.4)             | 115 (21.3)               | 87 (30.9)                | 20 (15.7)  |
| Clinical parameters     |                |                        |                          |                          |   |
| Laboratory results, mean (s.d.) | |                       |                          |                          |   |
| TSH, mIU/l              | 3.61 (9.00)    | 3.56 (8.20)            | 3.68 (8.40)              | 3.65 (12.82)             | 0.983 |
| FT4, pmol/l             | 15.44 (6.80)   | 15.13 (6.59)           | 15.23 (6.50)             | 17.21 (7.99)             | 0.007* |
| BMI, kg/m²              | 23.35 (3.96)   | 23.21 (3.96)           | 23.73 (4.12)             | 23.13 (3.51)             | 0.515 |
| SBP, mmHg               | 126.79 (17.42) | 127.49 (18.02)         | 124.68 (16.04)           | 127.87 (17.16)           | 0.299 |
| DBP, mmHg               | 74.55 (11.82)  | 74.85 (11.67)          | 74.06 (12.61)            | 74.18 (10.97)            | 0.802 |
| LDL-C, mmol/l           | 2.69 (0.91)    | 2.67 (0.90)            | 2.74 (0.89)              | 2.71 (1.03)              | 0.834 |
| Fasting glucose, mmol/l | 1.22 (0.81)    | 1.21 (0.80)            | 1.25 (0.95)              | 1.23 (0.46)              | 0.924 |
| Triglyceride, mmol/l    | 5.45 (1.14)    | 5.48 (1.19)            | 5.34 (1.03)              | 5.48 (1.13)              | 0.556 |
| eGFR, ml/min/1.73 m²    | 136.16 (36.79) | 135.65 (37.06)         | 137.08 (35.48)           | 136.32 (38.70)           | 0.688 |
| Previous ATD            | 731 (77.0)     | 418 (77.4)             | 217 (77.0)               | 96 (75.6)                | 0.908 |
| Previous RAI            | 86 (9.1)       | 50 (9.3)               | 24 (8.5)                 | 12 (9.5)                 | 0.927 |
| Disease status before surgery | |                       |                          |                          |   |
| GD duration, (months), mean (s.d.) | |                       |                          |                          |   |
| <6 months               | 34.19 (31.11)  | 33.67 (30.91)          | 34.84 (30.94)            | 34.93 (32.50)            | 0.040 |
| >6 months               | 439 (46.3)     | 257 (47.6)             | 125 (44.3)               | 57 (44.9)                | 0.840 |
| LT4 replacement         | |                       |                          |                          | 0.636 |
| LT4 dose (µg/kg/day)    | 1.57 (0.37)    | 1.59 (0.34)            | 1.50 (0.39)              | 1.69 (0.39)              | 0.008* |
| ≤50 µg/kg/day           | 78 (8.2)       | 41 (7.6)               | 25 (8.9)                 | 12 (9.4)                 | 0.369 |
| 75 µg/kg/day            | 120 (12.6)     | 69 (12.8)              | 41 (14.5)                | 10 (7.9)                 |   |
| 100 µg/kg/day           | 718 (75.7)     | 407 (75.4)             | 210 (74.5)               | 101 (79.5)               |   |
| 200 µg/kg/day           | 33 (3.5)       | 23 (4.3)               | 6 (2.1)                  | 4 (3.1)                  |   |
| Comorbidities           | |                       |                          |                          |   |
| CHD                     | 7 (0.7)        | 5 (0.9)                | 1 (0.4)                  | 1 (0.8)                  | 0.679 |
| HF                      | 23 (2.4)       | 19 (3.5)               | 2 (0.7)                  | 2 (1.6)                  | 0.036 |
| Stroke                  | 10 (1.1)       | 4 (0.7)                | 3 (1.1)                  | 3 (2.4)                  | 0.166 |
| AF                      | 42 (4.4)       | 28 (5.2)               | 13 (4.6)                 | 1 (0.8)                  | 0.166 |
| DM                      | 44 (4.6)       | 27 (5.0)               | 9 (3.2)                  | 8 (6.3)                  | 0.087 |
| HT                      | 72 (7.6)       | 45 (8.3)               | 13 (4.6)                 | 14 (11.0)                | 0.052 |
| Ophthalmopathy          | 400 (42.2)     | 244 (45.2)             | 96 (34.0)                | 60 (47.2)                | 0.004* |
| Cancer                  | 31 (3.3)       | 13 (2.4)               | 9 (3.2)                  | 7 (1.7)                  | 0.037* |
| CCI†, mean (s.d.)       | 1.10 (1.38)    | 1.18 (1.40)            | 0.83 (1.24)              | 1.39 (1.51)              | <0.001* |
| CCI‡                     | |                       |                          |                          | <0.001* |

Values are n (%) unless otherwise indicated. TSH, thyroid-stimulating hormone; FT4, free thyroxine; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; LT4, levothyroxine; ATD, anti-thyroid drug; RAI, radioactive iodine; CHD, coronary heart disease; HF, heart failure; AF, atrial fibrillation; DM, diabetes; HT, hypertension; CCI, Charlson comorbidity index. *Significant difference (P < 0.05) between groups by univariable linear regression or binary logistic regression. †The calculation of CCI does not include acquired immune deficiency syndrome.
patients with GD included in the analysis was determined as the date of complete or total thyroidectomy. Patients were followed from the index date and censored at the date of death, outcome events, and the last health service utilization, whichever came first.

Statistical analyses

The baseline characteristics of all patients were summarized with descriptive statistics. Multiple imputation was applied to address the missing data. The incidence rate of each outcome event was calculated using the number of event cases divided by the person-years. Multivariable Cox proportional hazards models were conducted with multiply imputed data sets to determine the association between thyroid status after thyroid surgery and the outcome events. Estimation models performed in the comparisons across three groups were adjusted for variables at baseline. Results estimated from the Cox hazards models were shown as HRs and their 95 per cent confidence intervals (c.i.). Kaplan–Meier survival curves were plotted to study the survival probabilities of each outcome event by groups over an interval of 10-year follow-up.

Sensitivity analyses were performed to test the robustness of the findings from primary analyses. The risk comparisons were conducted across groups by censoring the follow-up interval at 5 or 10 years after surgery. To compare the impact of achieving euthyroidism early on the long-term outcomes, sensitivity analyses were compared according to thyroid status at 6 months, 12 months, and at both 6 and 12 months. The first analysis compared abnormal thyroid status and euthyroidism at both 6 months and 12 months, and the second analysis compared achieving euthyroidism only at 6 months or 12 months and obtaining persistently normal thyroid status.

Statistical analyses were performed with STATA version 16.0, (StataCorp, College Station, Texas, USA). P values <0.05 were indicated to be significant.

Results

Figure 1 shows the flow of patients in this study. Between 2006 and 2018, 949 eligible patients were included in the analysis of the study; 540 (56.9 per cent) were in the euthyroidism group, 282

| Event                  | Cumulative incidence | Crude incidence rate (cases/1000 person-years) | Median follow-up interval (months) |
|------------------------|----------------------|-----------------------------------------------|-----------------------------------|
|                        | Cases with event     | Rate (%)                                      | Estimate                          | 95% c.i.*                  | Person-years |
| Total (n = 949)        |                      |                                               |                                   |                          |              |
| All-cause mortality    | 10                   | 1.1                                           | 1.75                              | (0.84, 3.22)              | 5709         | 68           |
| CVD                    | 19                   | 2.1                                           | 3.38                              | (2.04, 5.28)              | 5619         | 67           |
| Ophthalmopathy         | 89                   | 16.2                                          | 16.92                             | (13.59, 20.82)            | 5260         | 65           |
| Cancer                 | 51                   | 5.6                                           | 9.35                              | (6.96, 12.29)             | 5455         | 65           |
| Euthyroidism (n = 540) |                      |                                               |                                   |                          |              |
| All-cause mortality    | 6                    | 1.1                                           | 1.96                              | (0.72, 4.26)              | 3064         | 64           |
| CVD                    | 10                   | 2.0                                           | 3.32                              | (1.59, 6.10)              | 3014         | 64           |
| Ophthalmopathy         | 47                   | 15.9                                          | 16.45                             | (12.09, 21.88)            | 2857         | 58           |
| Cancer                 | 26                   | 4.9                                           | 8.86                              | (5.79, 12.99)             | 2933         | 60           |
| Hypothyroidism (n = 282) |                    |                                               |                                   |                          |              |
| All-cause mortality    | 3                    | 1.1                                           | 1.59                              | (0.33, 4.66)              | 1883         | 78           |
| CVD                    | 8                    | 2.9                                           | 4.33                              | (1.87, 8.53)              | 1848         | 74           |
| Ophthalmopathy         | 29                   | 15.6                                          | 16.98                             | (11.37, 24.38)            | 1708         | 73           |
| Cancer                 | 14                   | 5.1                                           | 7.70                              | (4.21, 12.93)             | 1817         | 74           |
| Hyperthyroidism (n = 127) |                  |                                               |                                   |                          |              |
| All-cause mortality    | 1                    | 0.8                                           | 1.31                              | (0.03, 7.30)              | 763          | 72           |
| CVD                    | 1                    | 0.8                                           | 1.32                              | (0.03, 7.36)              | 757          | 73           |
| Ophthalmopathy         | 13                   | 19.4                                          | 18.70                             | (9.96, 31.97)             | 695          | 72           |
| Cancer                 | 11                   | 9.3                                           | 15.60                             | (7.79, 27.92)             | 705          | 68           |

CVD, cardiovascular disease. *95 per cent c.i. of incidence rates were constructed by Poisson distribution.

Table 3 Hazard ratios of all-cause mortality, cardiovascular diseases, Graves’ ophthalmopathy, and cancer according to thyroid status

| Event                  | Hypothyroidism versus euthyroidism | Hyperthyroidism versus euthyroidism |
|------------------------|-----------------------------------|-----------------------------------|
|                        | HR 95% c.i. P                     | HR 95% c.i. P                     |
| Primary analysis*      |                                   |                                   |
| All-cause mortality    | 1.71 (0.86, 3.40) 0.125           | 0.41 (0.13, 1.25) 0.116           |
| CVD                    | 4.20 (2.37, 7.44) <0.001†          | 0.84 (0.29, 2.43) 0.745           |
| Ophthalmopathy         | 1.05 (0.84, 1.30) 0.682           | 0.99 (0.75, 1.31) 0.938           |
| Cancer                 | 1.16 (0.86, 1.57) 0.332           | 2.14 (1.55, 2.97) <0.001†         |

CVD, cardiovascular disease; *Primary model is adjusted for age, sex, BMI, thyroid-stimulating hormone, free thyroxine, low-density lipoprotein cholesterol, systolic/diastolic blood pressure, fasting glucose, triglyceride, estimated glomerular filtration rate, history of cardiovascular disease, diabetes, and hypertension, previous treatment with anti-thyroid drugs and radioiodine therapy, levothyroxine dosage, Graves’ disease duration, and Charlson comorbidity index. †Significant at 0.05 level by multivariable Cox proportional hazard regression model.
(29.7 per cent) were in the hypothyroidism group, and 127 (13.4 per cent) were in the hyperthyroidism group respectively. There was no difference in all baseline variables between the patients excluded and those included in this present study (Table S2).

Table 1 displays the baseline characteristics of patients with GD undergoing total thyroidectomy. The mean(s.d.) age of all study participants was 41.70(12.67) years, and 809 (85.3 per cent) were aged under 60 years. Their mean disease duration of GD before undergoing thyroidectomy was 34.19 months. The mean(s.d.) dose of levothyroxine was higher in the hyperthyroidism group at 1.69(0.39) µg/kg/day than that in the euthyroidism group (1.59(0.34) µg/kg/day) and hypothyroidism (1.50(0.39) µg/kg/day) group. The proportion of patients with hyperthyroidism using a 100 µg/day dosage of levothyroxine was 82.1 per cent; higher than that in those with euthyroidism (78.7 per cent) and hypothyroidism (76.1 per cent). Of the cohort, 731 (77.0 per cent) had pre-treatment with ATDs and 86 (9.1 per cent) received RAI therapy. No difference in the proportions having pre-treatment with ATDs and RAI was found across the groups.

Table 2 presents the incidence rate of primary outcome events in participants over the follow-up interval. With a total follow-up of 5709 person-years, all individuals in the study had a median follow-up of 68 months. Patients in the hypothyroidism group had a higher incidence rate of CVD (euthyroidism versus hypothyroidism versus hyperthyroidism, 3.32 versus 4.33 versus 1.32 per 1000 person-years). The incidence rate of cancer was higher in the hyperthyroidism group (euthyroidism versus hypothyroidism versus hyperthyroidism, 8.86 versus 7.70 versus 15.60 per 1000 person-years) than in the euthyroidism and hypothyroidism group. The individuals in the hyperthyroidism group had a slightly higher incidence rate of ophthalmopathy (euthyroidism versus hypothyroidism versus hyperthyroidism, 16.45 versus 16.98 versus 18.70 per 1000 person-years).

Table 3 shows the risk comparisons of outcome events estimated by multivariable Cox proportional hazard models. Compared with those obtaining euthyroidism shortly after thyroidectomy, patients in the hypothyroidism group were at an increased risk of CVD (HR = 2.14, 95 per cent c.i. 1.55 to 2.97, P < 0.001) and patients in the hyperthyroidism group had a higher risk of cancer (HR = 2.14, 95 per cent c.i. 2.14 to 2.97, P < 0.001). No significant difference was observed in all-cause mortality and Graves’ ophthalmopathy across the three groups.

Figure 2 shows the Kaplan–Meier curves over a 10-year follow-up interval in patients with GD by different thyroid status within a short interval after thyroidectomy. Compared with individuals who achieved euthyroidism shortly after surgery, the survival curves showed that a greater risk of CVD was observed in patients who were hypothyroid, whereas a higher risk of cancer was found in patients who were...
hypothyroid. Similar distributions of survival curves were observed in the other estimations of all-cause mortality and ophthalmopathy across groups. Table S3 indicates the patients assigned to three groups according to their thyroid status at 6 months, 12 months, and both at 6 and 12 months after surgery. Results from the sensitivity analyses were consistent with those from the primary analysis. Compared with euthyroid patients at 6 months, increased risks of CVD (HR = 2.83, 95 per cent c.i. 1.48 to 5.38, P = 0.002) and cancer (HR = 1.62, 95 per cent c.i. 1.17 to 2.23, P = 0.003) were observed in hypothyroid patients and a higher risk of cancer (HR = 1.83, 95 per cent c.i. 1.23 to 2.71, P = 0.003) was found in hyperthyroid patients. Patients who were hypothyroid at 12 months after surgery were at an increased risk of CVD (HR = 4.24, 95 per cent c.i. 1.75 to 10.26, P = 0.001). The comparisons also showed a greater risk of cancer (HR = 2.33, 95 per cent c.i. 1.63 to 3.33, P < 0.001) in patients with hyperthyroidism than in those with euthyroidism at 12 months. Moreover, compared with patients who achieved euthyroidism both at 6 months and at 12 months, the risk of cancer increased in patients who only achieved euthyroidism at 6 months combined with abnormal thyroid status at 12 months (HR = 2.33, 95 per cent c.i. 1.51 to 3.61, P < 0.001) and in those who were at abnormal thyroid status at 6 months but achieved euthyroidism at 12 months (HR = 2.52, 95 per cent c.i. 1.60 to 3.97, P < 0.001).

Table S4 presents the sensitivity analyses performed by estimation models censoring the interval at 5-year and 10-year follow-ups. Most of the sensitivity analyses were in line with the main estimations. Compared with the euthyroidism group, hypothyroidism was associated with a higher risk of CVD, and hyperthyroidism was associated with a higher risk of cancer at the 5-year and 10-year follow-ups. A higher risk of all-cause mortality (HR = 3.32, 95 per cent c.i. 1.06 to 10.25, P = 0.039) was identified in patients with hyperthyroidism than in euthyroid individuals at the 5-year follow-up.

Discussion

In line with the initial hypothesis, the present study shows that individuals who attained biochemical euthyroidism early after their complete or total thyroidectomy for GD had lower subsequent risks of morbidity than those who did not. To account for possible fluctuations in thyroid hormone levels shortly after surgery, this study screened the thyroid hormone levels over three pre-determined time points (6, 12, and 24 months) after thyroid surgery to determine patients who were truly euthyroid in the postoperative interval. From these results, patients who were hypothyroid were at a higher risk of CVD, whereas those who were hyperthyroid were at a higher risk of cancer than those who were euthyroid at 6 months or 12 months. Furthermore, relative to patients who attained euthyroidism both at 6 months and at 12 months, the risk of cancer increased among those who had not persistently achieved normal thyroid status.

There was no significant difference in all-cause mortality among patients who were hypothyroid or hyperthyroid and those individuals who achieved euthyroidism early after thyroidectomy. Consistent with this study, previous findings from other studies did not support that hypothyroidism or hyperthyroidism increases the risk of mortality.

A retrospective cohort study of 2730 patients with a 4-year follow-up by Rodondi et al. found that subclinical hypothyroidism was not associated with an increased risk of total mortality. In a large prospective cohort study estimating the association between baseline thyroid status and death, Cappola et al. also showed no difference in all-cause mortality between the subclinical hypothyroidism group and euthyroidism group. Contrary to these findings, the retrospective cohort study by Selmer et al. reported that overt and subclinical hypothyroidism was associated with a higher risk of all-cause mortality and Mitchell et al. found that patients with hypothyroidism and hyperthyroidism had increased mortality risk compared with those who had normal thyroid status. However, these studies relying solely on serum TSH levels may not reliably reflect the true underlying thyroid status. Therefore, the current findings may provide more robust evidence to explain the impact of thyroid dysfunction on the subsequent risk of mortality.

Given that hypothyroidism or hyperthyroidism is usually accompanied by impaired cardiac contractility, systolic or diastolic dysfunction, and systemic vascular resistance, clinical assessment is needed for the association between thyroid status after thyroid surgery and cardiovascular morbidities. From a meta-analysis involving 1898314 participants, Ning et al. found higher risks of ischaemic heart disease and cardiac mortality in patients with hypothyroidism than those with euthyroidism. In agreement with this, the present study shows a higher CVD risk in the hypothyroidism group compared with the euthyroidism group. This finding is also aligned with an individual analysis of 55287 participants, where subclinical hypothyroid patients who had higher TSH levels (10.00 mIU/l or greater) had increased risks of coronary heart disease events and related death compared with euthyroid individuals. It has been reported that low-density lipoprotein is increased in overt and subclinical hypothyroidism, and 90 per cent of patients with overt hypothyroidism had hypercholesterolemia. The increased lipid levels might contribute to explaining the higher risk of CVD associated with hypothyroidism.

Some studies did not support the association between cardiovascular morbidities and thyroid status. Martin et al. estimated the cross-sectional impact of thyroid status on cardiovascular events and did not find increased risks of stroke or myocardial infarction with abnormal thyroid status. Previous studies by Cappola et al. and Imazuzumi et al. showed no impact of subclinical hypothyroidism on cerebrovascular disease. The controversial data from articles, studies with strict criteria and convincing results are therefore merited. The survival analyses in the population-based cohort of the present study adjusted for many risk factors related to cardiovascular events (BMI, blood pressure, serum lipid levels, fasting glucose, and triglyceride), providing strengthened evidence.

Thyroid hormones have been reported to influence both cell multiplication of breast cancer and induce the process of angiogenesis of some cancer types. Correspondingly, a greater risk of breast cancer has been found in those patients diagnosed with hyperthyroidism than those who were not. In addition to studies indicating a higher cancer risk with thyroid dysfunction, the meta-analysis by Krashin et al. reported that subclinical and clinical hyperthyroidism increased the risk of several solid tumours, whereas hypothyroidism might reduce aggressiveness or delay the development of cancer. In agreement with these findings, the present study found a higher risk of cancer in hyperthyroid patients but not in hypothyroid individuals. Although previous research has demonstrated the impact of thyroid dysfunction on several cancer types, the present study primarily focused on the overall cancer risk in patients with GD after surgical therapy. The finding that hyperthyroidism was associated with a higher risk of cancer than euthyroidism after surgery has provided complementary evidence for exploring the
risk factors related to thyroid dysfunction for primary cancer in patients with GD.

Thyroid status may also affect the development of ophthalmopathy, although the present study did not support the impact of thyroid dysfunction on the increased risk of this event. Given that limited studies have estimated the impact of thyroid status on thyroid-associated orbitopathy, the research by Eckstein et al. showed that euthyroid/hypothyroid patients developed significantly less severe and less active ophthalmopathy symptoms than those with hyperthyroidism. The present study also found a relatively lower incidence rate of ophthalmopathy in euthyroid and hypothyroid patients than in those with hyperthyroidism. Moreover, patients with euthyroid/hypothyroid orbitopathy were found to have less impaired quality of life and working ability than those with hyperthyroid orbitopathy. Therefore, patients undergoing thyroidectomy need to be monitored for the effects of thyroid abnormality on clinical manifestations at follow-up.

There are some limitations to the present study. First, the results may not be generalizable to older patients and those who had not undergone total thyroidectomy and used levotyroxine for the treatment of GD. Second, data on triiodothyronine is not sufficient, resulting in missing some overtly hypothyroid patients to be included in the analysis. Third, given that the group assignment was based on the test results of thyroid hormone levels of TSH and FT4, the change in thyroid hormone levels may lead to misclassification for transient thyroid abnormality. In terms of strengths, this is the first paper to estimate the impact of thyroid status after total thyroidectomy on all-cause mortality and other long-term outcomes. Few large retrospective studies have access to baseline and follow-up data. Risk estimations performed by models for longitudinal effects had adjustments with clinical parameters, disease duration, levotyroxine use, and history of co-morbidities, reducing confounding bias. This study could provide novel evidence for the effects of thyroid status on adverse outcomes among patients with GD undergoing thyroidectomy.

Obtaining euthyroidism shortly after thyroid surgery was associated with a lower risk of CVD compared with hypothyroidism, and a lower risk of cancer than hyperthyroidism in patients with GD undergoing thyroidectomy. Moreover, being euthyroid both at 6 months and at 12 months decreased the risk of cancer than achieving euthyroidism only at 6 months or at 12 months. Therefore, early monitoring and control of thyroid hormone levels after thyroid surgery is recommended as part of GD management.

### Funding
This study was funded by the Health and Medical Research Fund Research Fellowship Scheme, Food and Health Bureau, Hong Kong SAR (ref. no. 17181051).

### Acknowledgements
We thank the Central Panel on Administrative Assessment of External Data Requests, Hong Kong Hospital Authority Head Office, for the provision of hospital authority data. X.L. and C.K.H.W. contributed equally as first authors.

### Disclosure
The authors declare no conflict of interest.

### Supplementary material

#### Supplementary material
Supplementary material is available at BJS Open online.

#### Data availability

Due to ethical concerns, supporting data cannot be made openly available.

### References

1. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 2018;7:167–186
2. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343–1421
3. Vasileiou M, Gilbert J, Fishburn S, Boelaert K, Guideline C. Thyroid disease assessment and management: summary of NICE guidance. BMJ 2020;368:m41
4. Liu X, Wong CKH, Chan WWL, Tang EHM, Woo YC, Liu SYW et al. Long-term outcome of patients treated with antithyroid drugs, radioactive iodine or surgery for persistent or relapsed Graves’ disease. Br J Surg 2022;109:381–389
5. Giesecke P, Frykman V, Wallin G, Lönn S, Discacciati A, Törring et al. First paper to estimate the impact of surgery versus radioiodine treatment for hyperthyroidism. Br J Surg 2018;105:279–286
6. Elnahla A, Attia AS, Khadra HS, Munshi R, Shalaby H, Lee GS et al. Impact of surgery versus medical management on cardiovascular manifestations in Graves disease. Surgery 2021;169:82–86
7. Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee Bj et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves’ disease. JAMA Ophthalmol 2015;133:290–296
8. Liu X, Wong CKH, Chan WWL, Tang EHM, Woo YC, Lam CLK et al. Outcomes of Graves’ disease patients following antithyroid drugs, radioactive iodine, or thyroidectomy as the first-line treatment. Ann Surg 2021;273:1197–1206
9. Brun VH, Eriksen AH, Selseth R, Johansson K, Vik R, Davidsen B et al. Patient-tailored levotyroxine dosage with pharmacokinetic/pharmacodynamic modeling: a novel approach after total thyroidectomy. Thyroid 2021;31:1297–1304
10. Olubowale O, Chadwick DR. Optimization of thyroxine replacement therapy after total or near-total thyroidectomy for benign thyroid disease. Br J Surg 2006;93:57–60
11. Rodondi N, den Elzen WPJ, Bauer DC, Cappola AR, Razvi S, Walsh JP et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010;304:1365–1374
12. Molinaro S, Iervasi G, Lorenzoni V, Landi P, Srebot V, Mariani F et al. Persistence of mortality risk in patients with acute cardiac diseases and mild thyroid dysfunction. Am J Med Sci 2012;343:65–70
13. Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 2012;60:730–737
14. Wang W, Guan H, Gerdes AM, Iervasi G, Yang Y, Tang YD. Thyroid status, cardiac function, and mortality in patients...
with idiopathic dilated cardiomyopathy. J Clin Endocrinol Metab 2015;100:3210–3218
15. Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, Brix TH, Hegedus L. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid 2019;29:332–340
16. Palit TK, Miller CC III, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res 2000;90:161–165
17. Wong MC, Jiang JY, Tang JL, Lam A, Fung H, Mercer SW. Health services research in the public healthcare system in Hong Kong: an analysis of over 1 million antihypertensive prescriptions between 2004–2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. BMC Health Serv Res 2008;8:138
18. Wong AYS, Root A, Douglas IJ, Chui CS, Chan EW, Ghebremichael-Weideselessie Y et al. Cardiovascular outcomes associated with use of clarithromycin: population-based study. BMJ 2016;352:h6926
19. Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. Epidemiology and natural history of Wilson’s disease in the Chinese: a territory-based study in Hong Kong between 2000 and 2016. World J Gastroenterol 2017;23:7716–7726
20. Ito M, Miyachi A, Kang S, Hisakado M, Yoshioka W, Ide A et al. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. Eur J Endocrinol 2015;173:333–340
21. de Ven ACV, Netaea-Maier RT, de Vetg F, Ross HA, Sweep FCGJ, Kiemeney LA et al. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol 2014;171:183–191
22. Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA Netw Open 2020;3:e1920745
23. Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation 2017;136:2100–2116
24. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219–242
25. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005;165:2460–2466
26. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033–1041
27. Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014;99:2372–2382
28. Mitchell JE, Hellkamp AS, Mark DB, Anderson J, Johnson GW, Poole JE et al. Thyroid function in heart failure and impact on mortality. JACC Heart Fail 2013;1:48–55
29. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116:1725–1735
30. Ning Y, Cheng YJ, Liu LJ, Sara JDS, Cao ZY, Zheng WP et al. What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Med 2017;15:21
31. Duntas LH. Thyroid disease and lipids. Thyroid 2002;12:287–293
32. StaubJJ, Althaus BU, Engler H, Ryff AS, Trabucco P, Marquardt K et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992;92:631–642
33. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002;87:1533–1538
34. Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: the atherosclerosis risk in communities (ARIC) study. J Clin Endocrinol Metab 2017;102:3306–3315
35. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004;89:3365–3370
36. Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson UB, Malm J et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer 2012;131:2126–2133
37. Yang HM, Holowko N, Grassmann F, Eriksson M, Hall P, Czene K. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med 2020;18:225
38. Krashin E, Piecielko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne) 2019;10:59
39. Eckstein AK, Losch C, Glowacka D, Schott M, Mann K, Esser J et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol 2009;93:1052–1056
40. Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S et al. Prevalence, phenotype, and psychosocial well-being in euthyroid/hypothyroid thyroid-associated orbitopathy. Thyroid 2015;25:942–948